retatrutide not losing weight UK Guide: Key Facts on the New Weight-Loss Drug Retatrutide, an Amazing Future for

This was surprising given that GLP-1 agonists do increase heart rate slightly in clinical settings

Ideal for those aiming to reduce calorie intake without relying on GLP-1 medications or for individuals on GLP-1 therapies who want to maintain a lower dose with a more steady appetite-suppressing effect

For tirzepatide users, neither supplement has known interactions with GLP-1 therapy, making them safe additions to the regimen

Retatrutide is the only obesity-focused drug in advanced Phase 3 development that activates glucagon receptors at therapeutic doses

Weight was modestly but universally lower in the treatment arm of all of the aforementioned trials